We are live on ! Find out more
LLY icon

Eli Lilly

2,446 hedge funds and large institutions have $255B invested in Eli Lilly in 2022 Q2 according to their latest regulatory filings, with 211 funds opening new positions, 869 increasing their positions, 916 reducing their positions, and 81 closing their positions.

New
Increased
Maintained
Reduced
Closed

160% more first-time investments, than exits

New positions opened: 211 | Existing positions closed: 81

79% more funds holding in top 10

Funds holding in top 10: 102183 (+81)

13% more capital invested

Capital invested by funds: $225B → $255B (+$29.6B)

4% more funds holding

Funds holding: 2,3462,446 (+100)

4% more call options, than puts

Call options by funds: $1.87B | Put options by funds: $1.79B

0.09% more ownership

Funds ownership: 82.88%82.96% (+0.09%)

5% less repeat investments, than reductions

Existing positions increased: 869 | Existing positions reduced: 916

Holders
2,446
Holders Change
+100
Holders Change %
+4.26%
% of All Funds
41.2%
Holding in Top 10
183
Holding in Top 10 Change
+81
Holding in Top 10 Change %
+79.41%
% of All Funds
3.08%
New
211
Increased
869
Reduced
916
Closed
81
Calls
$1.87B
Puts
$1.79B
Net Calls
+$78.5M
Net Calls Change
+$267M
Name Holding Trade Value Shares
Change
Change in
Stake
DWT
426
Dorsey & Whitney Trust
South Dakota
$13.4M -$646K -2,153 -5%
CTC
427
Central Trust Company
Missouri
$13.4M -$80.7K -269 -0.6%
Bessemer Group
428
Bessemer Group
New Jersey
$13.3M -$301K -1,003 -2%
VIP
429
Vantage Investment Partners
Missouri
$13.3M -$1.6M -5,341 -12%
NAM
430
NTV Asset Management
West Virginia
$13.2M -$164K -546 -1%
MA
431
Montag & Associates
Georgia
$13.2M -$139K -463 -1%
TF
432
Tompkins Financial
New York
$13.1M -$183K -608 -1%
ACI
433
Alpha Cubed Investments
California
$13.1M -$2.19M -7,285 -15%
WDA
434
Wendell David Associates
New Hampshire
$13M -$10.5K -35 -0.1%
CCMINC
435
Cardinal Capital Management Inc (North Carolina)
North Carolina
$12.9M -$113K -375 -0.9%
ETC
436
Exchange Traded Concepts
Oklahoma
$12.9M +$11.9M +39,566 +19,300%
CAC
437
Core Alternative Capital
Georgia
$12.9M +$1.94M +6,452 +19%
AMCA
438
Arthur M. Cohen & Associates
Illinois
$12.9M -$215K -715 -2%
FAT
439
First American Trust
California
$12.8M +$259K +864 +2%
CAN
440
Cetera Advisor Networks
California
$12.7M +$782K +2,606 +7%
MAM
441
Meeder Asset Management
Ohio
$12.6M +$1.2M +4,010 +12%
DWM
442
Dakota Wealth Management
Florida
$12.6M -$439K -1,462 -4%
TRCT
443
Tower Research Capital (TRC)
New York
$12.5M -$20.1M -67,003 -63%
SWM
444
Spire Wealth Management
Virginia
$12.5M +$8.68M +28,932 +303%
LSA
445
L & S Advisors
California
$12.4M +$5.95M +19,812 +108%
KWILP
446
Kiwi Wealth Investments Limited Partnership
New Zealand
$12.3M +$2.81M +9,363 +33%
LCM
447
LVM Capital Management
Michigan
$12.3M -$897K -2,988 -7%
CHC
448
City Holding Co
West Virginia
$12.3M -$579K -1,929 -5%
Impax Asset Management Group
449
Impax Asset Management Group
United Kingdom
$12.2M -$173K -575 -2%
HWAM
450
Hennion & Walsh Asset Management
New Jersey
$12.2M -$1.5M -5,006 -12%

LLY Hedge Fund Activity: Q2 2022 in Review

2,446 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Eli Lilly (LLY) for Q2 2022, worth a combined $255B — up 13% from $225B a quarter earlier.

Buyers outnumbered sellers: 211 funds opened new LLY positions and 81 closed out — a net gain of 130 holders — while 869 added to existing stakes and 916 trimmed.

The largest buyer was Capital World Investors, adding an estimated $1.92B. The largest seller was Capital International Investors, cutting an estimated $1.16B.

  • 2,446 institutional investors held Eli Lilly (LLY) as of Q2 2022, up from 2,346 in Q1 2022.
  • Funds reported $255B of Eli Lilly stock for Q2 2022, up 13% quarter-over-quarter.
  • 211 funds opened new Eli Lilly positions in Q2 2022 and 81 closed out, a net change of +130 holders.
  • The largest Eli Lilly buyer in Q2 2022 was Capital World Investors, an estimated $1.92B added.
  • The largest Eli Lilly seller in Q2 2022 was Capital International Investors, an estimated $1.16B sold.

Based on aggregated 13F filings for Q2 2022.